Epigenetics: The Silent Future of Orthopedic Treatments
Why Read? Get a glimpse of the future of orthopedics, that’s not AI, not imaging, not robotics, and not metal. […]
Why Read? Get a glimpse of the future of orthopedics, that’s not AI, not imaging, not robotics, and not metal. […]
I’ve been knee-deep in the ortho startup world for decades—working in three of them, chatting with founders on my blog
Tiger’s Take We are moving away from the era of “one size fits all” orthopedics. We’ve mastered the metal and
Why read In our industry, the landscape is dominated by mechanical innovations, but some of the biggest breakthroughs are non-
In the quest for orthopedic innovation, many startups chase the illusion of the quick win—building a product. Few grasp the
Tiger’s Take In my view, the Tecomet-Orchid merger is the definitive signal that the “supply chain as a service” model
In orthopedic M&A, one audacious open letter stands as a masterclass in disruption. Back in 2003, Smith & Nephew had
Tiger’s Take This acquisition may trigger more fundings and more M&A in the Sports Med space. About a year ago,
Your team defines your company—it’s that straightforward.We all know this deep down: It’s not the tech, the office space, the
Many many ortho sales pros are frustrated in 2026. This is a rant that I wrote last night, but some
Why Read ? Monopolies are the holy grail if you can create one and maintain it for years. I saw
We are all learning and growing in our careers. But what happens when your growth slows down? You may not
What can we learn from Big Ortho about moats? I’ve seen countless startups rise and fall, and let me tell
In our ortho industry, we spend an incredible amount of time obsessing over implant geometry, surface coatings, and robotic precision.
Market conditions in Ortho are tighter than a locked pedicle screw these days—extended sales processes, rising costs, regulatory hurdles, and
Your monthly ortho industry DASHBOARD – no-ads, no bias, just my insider thoughts with exclusive predictions, trends, recent deals, funding
Why Read? Orthopedic CEOs have a tough job. Challenges come at them from all directions. They are contending with lengthened
I’ve seen just about every sales model under the sun. From the $50K box openers at Arthrex to independent distributors
Often there is a silent killer lurking beneath the skin, turning orthopedic implants into ticking time bombs of infection—resistant to
The Medline IPO is a strong signal. Maybe we will see more Ortho PE IPOs in 2026. I would watch
In a poignant LinkedIn post that has resonated across the orthopedic community, Robert Clayton, President of the British Orthopaedic Foot
Why Read Over time in orthopedics, we have all seen the focus shift away from clinical innovation and patient outcomes
NOTE: This article will tell you who Reinhold is based on his early work. It was written in 2011 and
Our industry has created fortunes for those who navigate it with precision. From trailblazing entrepreneurs like Dane Miller or Maurice
The appetite for risk in orthopedic medical device companies evolves dramatically with their size—reflecting changes in resources, priorities, and stakeholder
Over the years I have watched many orthopedic companies rename themselves, or rebrand themselves or pivot. Most of the time
I am watching the soft tissue repair revolution heating up fast. Rotator cuff tears alone affect millions, with re-tear rates
If you are not an OrthoStreams subscriber, you can read the full details here – https://lnkd.in/g7dS_B4K Tiger Buford and Andrea Davis are brokering
My perspective is completely different from the BoneZone piece this week, Robots Are Setting the New Standard of Surgical Care,
Many startups are struggling to raise capital and rather than drive off the cliff, there is an option available –
I know Product Development because I led PD for 35 years. People in organized ortho companies call me asking: “Why
Why Read If you’re leading or working in an orthopedics or medtech engineering and innovation team, stop scrolling and read
I am watching the joint preservation movement growing rapidly. Patients do not trust their orthopedists 100% any longer. Especially when
As we prepare to enter 2026, Surgeons are still being blasted with features, features, features at medical shows and over
Why This Matters As someone who’s been covering ortho innovations for years, I see RepSource as a breath of fresh
Today, we’re talking robots. Not the flashy surgical arms stealing the spotlight in the OR, but the unsung heroes that
I am thrilled to share the inaugural edition of The Tiger Dashboard with everyone—for this month only. These are my
In our industry, many ortho surgeons often stick with the products they know, even when newer options hit the market.
If you’ve been in the ortho industry for any time, you know the big dogs like Stryker, Zimmer Biomet, and
This new startup is pioneering Therapeutic Hardware with 3D-printed porous pedicle screws that mimic bone’s trabecular structure to enhance integration,
Heard on the street. This is going to be a wild few months with a ton of disruption in people.
Too many startup CEOs call me with excitement about their company, when its not a company yet. It’s a science
Why Read? This article explores a proven “ASC-only” strategy via an 8-step playbook for entrepreneurs, covering ASC-optimized product design, partnerships,
Shame on Aesculap: A $38.5M Settlement Exposes Device Failures, Kickbacks, and Why Foreign Ortho Giants Hesitate on the U.S. Market
What happened at NASS this year? Spoiler: It was less “spine-tingling breakthroughs” and more “spine-tingling hangovers from ghost tours.” Let’s
Meduloc is revolutionizing small-bone trauma care with its FDA-cleared, minimally invasive nitinol intramedullary implants that deliver precise reduction, rotational stability,
Hey folks, Tiger Buford here with a quick dive into the spine market as NASS 2025 kicks off in Denver.
There is a seismic shift underway in spine. Traditional rigid fusions, once the standard for treating degenerative disc disease, are
Orthopedists may have more employment freedom as Non-Compete Agreements continue to evolve in the US. While the FTC’s proposed nationwide
In orthopedic startups—where innovation in joint replacements, regenerative therapies, or AI-driven surgical planning can make or break your venture—it’s easy